Company Overview

Xeris Biopharma Holdings, Inc. is a U.S.-based specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusion therapies that address unmet needs in endocrinology, neurology, and other chronic disease areas. The company operates within the biopharmaceutical and specialty pharmaceuticals industries, with a core emphasis on improving drug delivery through formulation science that enhances stability, ease of use, and patient adherence.

Xeris generates revenue primarily from the commercialization of proprietary products and from product sales through specialty pharmacy and institutional channels. Its key products include Gvoke, a ready-to-use glucagon for the treatment of severe hypoglycemia; Recorlev, an oral therapy for endogenous Cushing’s syndrome; and Keveyis, a carbonic anhydrase inhibitor for primary periodic paralysis. The company’s strategic advantage lies in its formulation platforms that eliminate reconstitution requirements and cold-chain constraints. Xeris was founded in 2005 and became a publicly traded company in 2018. In 2021, it evolved into its current form through the merger with Strongbridge Biopharma, significantly expanding its commercial portfolio.

Business Operations

Xeris operates through a single integrated reporting structure but manages its business across distinct therapeutic franchises centered on endocrinology and rare diseases. Revenue is generated from U.S. product sales of Gvoke, Recorlev, and Keveyis, as well as from licensing and collaboration arrangements related to its formulation technologies. The company’s operations include research and development, regulatory affairs, manufacturing oversight through third-party contract manufacturers, and a specialized commercial sales organization.

The company controls proprietary formulation technologies, including its non-aqueous and aqueous ready-to-use injectable platforms, which are applied to both internal pipeline assets and partnered programs. Xeris conducts most commercial activities in the United States, while certain clinical development and manufacturing activities involve international partners and contract organizations. Its key subsidiary, Xeris Pharmaceuticals, Inc., holds the majority of operating assets and intellectual property.

Strategic Position & Investments

Xeris’ strategy is centered on maximizing the value of its commercial products while advancing a focused pipeline of lifecycle management and line-extension opportunities. Growth initiatives include expanding prescriber adoption of Gvoke in diabetes care, increasing awareness and diagnosis rates for Cushing’s syndrome to support Recorlev, and maintaining leadership in the treatment of primary periodic paralysis through Keveyis. The company also invests in post-marketing studies and formulation improvements to extend product lifecycles.

A pivotal strategic investment was the acquisition of Strongbridge Biopharma, which added two FDA-approved rare disease products and an established endocrinology-focused commercial infrastructure. Xeris continues to evaluate selective business development opportunities that align with its formulation expertise and commercial footprint, while maintaining financial discipline amid ongoing investments in R&D and commercialization.

Geographic Footprint

Xeris is headquartered in the United States, with its principal executive offices located in Chicago, Illinois. The company’s primary commercial market is North America, where it conducts the majority of its sales, marketing, and distribution activities. Clinical development programs and regulatory interactions are also predominantly U.S.-focused, reflecting its emphasis on FDA-approved therapies.

Internationally, Xeris maintains a limited but strategic presence through partnerships, contract manufacturing organizations, and certain ex-U.S. licensing arrangements. While it does not currently operate large-scale commercial infrastructure outside the U.S., its products may reach patients in select international markets via distribution partners, and the company retains the option to pursue broader global expansion through collaborations.

Leadership & Governance

Xeris is led by an experienced management team with backgrounds in specialty pharmaceuticals, endocrinology, and rare disease commercialization. The leadership emphasizes disciplined capital allocation, patient-centric product design, and leveraging formulation science to differentiate approved therapies in competitive and underserved markets.

Key executives include:

• John E. Shannon – President and Chief Executive Officer
• Steven M. Pieper – Chief Financial Officer
• Kenneth L. Johnson – Senior Vice President and Chief Commercial Officer
• Carolyn A. Daws – Senior Vice President and Chief Medical Officer
• Michael J. McLaughlin – Senior Vice President, Research and Development

The company is governed by a board of directors with experience across biotechnology, finance, and healthcare, and operates under standard U.S. public company governance practices as outlined in its SEC filings, including its Form 10-K and Form 10-Q disclosures.